Hodgkin lymphoma risk: Role of genetic polymorphisms and gene-gene interactions in DNA repair pathways

Molecular Carcinogenesis

Volumn 50, Issue 11, 2011, Pages 825-834

  Monroy, Claudia M ^a   Cortes, Andrea C ^a   Lopez, Mirtha ^a   Rourke, Elizabeth ^a   Etzel, Carol J ^a   Younes, Anas ^a   Strom, Sara S ^a   El Zein, Randa ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

DNA repair genes; Gene gene interaction; Hodgkin lymphoma

Indexed keywords

ADULT; ARTICLE; CANCER RISK; CONTROLLED STUDY; DNA REPAIR; DOUBLE STRANDED DNA BREAK; EXCISION REPAIR; FEMALE; GENE INTERACTION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; DNA; DNA REPAIR; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; YOUNG ADULT;

EID: 80054744234     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.20747     Document Type: Article

References (59)

1. American Cancer Society. Cancer facts and figures 2008, American Cancer Society. Atlanta, GA: American Cancer Society; 2008.
2. Re D, Zander T, Diehl V, Wolf J. Genetic instability in Hodgkin's lymphoma. Ann Oncol 2002; 13: 19-22.
3. Thoms KM, Baesecke J, Emmert B, et al. Functional DNA repair system analysis in haematopoietic progenitor cells using host cell reactivation. Scand J Clin Lab Invest 2007; 67: 580-588.
4. Holt SM, Scemama JL, Panayiotidis MI, Georgakilas AG. Compromised repair of clustered DNA damage in the human acute lymphoblastic leukemia MSH2-deficient NALM-6 cells. Mutat Res 2009; 674: 123-130.
5. Foroutan B, Ali Ruf A, Jerwood D, Anderson D. In vitro studies of DNA damage and its repair in cells from NHL patients with different p53 mutant protein status, resistant (p53(+)) and sensitive (p53(-)) to cancer chemotherapy. J Pharmacol Toxicol Methods 2007; 55: 58-64.
6. Ribas G, Gonzalez-Neira A, Salas A, et al. Evaluating Hap-Map SNP data transferability in a large-scale genotyping project involving 175 cancer-associated genes. Hum Genet 2006; 118: 669-679.
7. Hall J, Marcel V, Bolin C, et al. The associations of sequence variants in DNA-repair and cell-cycle genes with cancer risk: Genotype-phenotype correlations. Biochem Soc Trans 2009; 37: 527-533.
8. Seedhouse C, Faulkner R, Ashraf N, et al. Polymorphisms in genes involved in homologous recombination repair interact to increase the risk of developing acute myeloid leukemia. Clin Cancer Res 2004; 10: 2675-2680.
9. Scrideli CA, Tone LG. Polymorphisms of DNA repair genes and susceptibility to acute childhood lymphoblastic leukemia. Leuk Res 2007; 31: 759-763.
10. Ganster C, Neesen J, Zehetmayer S, et al. DNA repair polymorphisms associated with cytogenetic subgroups in B-cell chronic lymphocytic leukemia. Genes Chromosomes Cancer 2009; 48: 760-767.
11. Worrillow L, Roman E, Adamson PJ, et al. Polymorphisms in the nucleotide excision repair gene ERCC2/XPD and risk of non-Hodgkin lymphoma. Cancer Epidemiol 2009; 33: 257-260.
12. Wang SS, Maurer MJ, Morton LM, et al. Polymorphisms in DNA repair and one-carbon metabolism genes and overall survival in diffuse large B-cell lymphoma and follicular lymphoma. Leukemia 2009; 23: 596-602.
13. Monzo M, Brunet S, Urbano-Ispizua A, et al. Genomic polymorphisms provide prognostic information in intermediate-risk acute myeloblastic leukemia. Blood 2006; 107: 4871-4879.
14. Batar B, Güven M, Bariş S, et al. DNA repair gene XPD and XRCC1 polymorphisms and the risk of childhood acute lymphoblastic leukemia. Leuk Res 2009; 33: 759-763.
15. Joseph T, Kusumakumary P, Chacko P, et al. DNA repair gene XRCC1 polymorphisms in childhood acute lymphoblastic leukemia. Cancer Lett 2005; 217: 17-24.
16. Bhatla D, Gerbing RB, Alonzo TA, et al. DNA repair polymorphisms and outcome of chemotherapy for acute myelogenous leukemia: A report from the Children's Oncology Group. Leukemia 2008; 22: 265-272.
17. Rossi D, Gaidano G, Gloghini A, et al. Frequent aberrant promoter hypermethylation of O6-methylguanine-DNA methyltransferase and death-associated protein kinase genes in immunodeficiency-related lymphomas. Br J Haematol 2003; 123: 475-478.
18. El-Zein RA, Monroy CM, Etzel CJ, et al. Genetic polymorphisms in DNA repair genes as modulators of Hodgkin disease risk. Cancer 2009; 115: 1651-1659.
19. Sen P, Bailey NM, Hagemeister FB, Liang JC. Induction of chromosome breaks and sister chromatid exchanges in patients with Hodgkin's disease by two combination chemotherapy regimens of different leukemogenic potential. Cancer Res 1990; 50: 558-562.
20. Liang JC, Bailey NM, Gabriel GJ, et al. A new chemotherapy regimen for treatment of Hodgkin's disease associated with minimal genotoxicity. Leuk Lymphoma 1993; 9: 503-508.
21. Strom SS, Hess KR, Sigurdson AJ, Spitz MR, Liang JC. Evaluation of sister chromatid exchange and chromosome breaks in a cohort of untreated Hodgkin's disease patients. Cancer Epidemiol Biomarkers Prev 1997; 6: 291-293.
22. Hartge P, Brinton LA, Rosenthal JF, Cahill JI, Hoover RN, Waksberg J. Random digit dialing in selecting a population-based control group. Am J Epidemiol 1984; 120: 825-833.
23. Akaike H. A new look at the statistical model identification. IEEE Trans Automat Control 1984; AC-19: 716-723.
24. Ritchie MD, Hahn LW, Roodi N, et al. Multifactor-dimensionality reduction reveals high-order interactions among estrogen-metabolism genes in sporadic breast cancer. Am J Hum Genet 2001; 69: 138-147.
25. Breiman L, Friedman JN, Olsen RA. Classification and regression trees. Monterey: Wadsworth and Brooks/Cole; 1984.
26. Vogel U, Overvad K, Wallin H, et al. Combinations of polymorphisms in XPD, XPC and XPA in relation to risk of lung cancer. Cancer Lett 2005; 222: 67-74.
27. Sanyal S, Festa F, Sakano S, et al. Polymorphisms in DNA repair and metabolic genes in bladder cancer. Carcinogenesis 2004; 25: 729-734.
28. Shen H, Sturgis EM, Khan SG, et al. An intronic poly (AT) polymorphism of the DNA repair gene XPC and risk of squamous cell carcinoma of the head and neck: A case-control study. Cancer Res 2001; 61: 3321-3325.
29. Zhu Y, Yang H, Chen Q, et al. Modulation of DNA damage/DNA repair capacity by XPC polymorphisms. DNA Repair (Amst) 2008; 7: 141-148.
30. Vodicka P, Kumar R, Stetina R, et al. Genetic polymorphisms in DNA repair genes and possible links with DNA repair rates, chromosomal aberrations and single-strand breaks in DNA. Carcinogenesis 2004; 25: 757-763.
31. Zhu Y, Lai M, Yang H, et al. Genotypes, haplotypes and diplotypes of XPC and risk of bladder cancer. Carcinogenesis 2007; 28: 698-703.
32. Chen D, Jin G, Wang Y, et al. Genetic variants in peroxisome proliferator-activated receptor-gamma gene are associated with risk of lung cancer in a Chinese population. Carcinogenesis 2008; 29: 342-350.
33. Ma H, Xu L, Yuan J, et al. 2007; Tagging single nucleotide polymorphisms in excision repair cross-complementing group 1 (ERCC1) and risk of primary lung cancer in a Chinese population. Pharmacogenet Genomics 17: 417-423.
34. Schanz S, Castor D, Fischer F, et al. Interference of mismatch and base excision repair during the processing of adjacent U/G mispairs may play a key role in somatic hypermutation. Proc Natl Acad Sci USA 2009; 106: 5593-5598.
35. Caldecott KW, Aoufouchi S, Johnson P, et al. XRCC1 polypeptide interacts with DNA polymerase beta and possiblypoly (ADP-ribose) polymerase, and DNA ligase III is anovel molecular' nick-sensor' in vitro. Nucleic Acids Res 1996; 24: 4387-4394.
36. Abdel-Rahman SZ, El-Zein RA. The 399Gln polymorphism in the DNA repair gene XRCC1 modulates the genotoxic response induced in human lymphocytes by the tobacco-specific nitrosamine NNK. Cancer Lett 2000; 159: 63-71.
37. Duell EJ, Holly EA, Bracci PM, et al. A population-based study of the Arg399Gln polymorphism in X-ray repair cross-complementing group 1 (XRCC1) and risk of pancreatic adenocarcinoma. Cancer Res 2002; 62: 4630-4636.
38. Matullo G, Palli D, Peluso M, et al. XRCC1, XRCC3, XPD gene polymorphisms, smoking and 32P-DNA adducts in a sample of healthy subjects. Carcinogenesis 2001; 22: 1437-1445.
39. Dulic A, Bates PA, Zhang X, et al. BRCT domain interactions in the heterodimeric DNA repair protein XRCC1-DNA ligase III. Biochemistry 2001; 40: 5906-5913.
40. Taylor RM, Thistlethwaite A, Caldecott KW. Central role for the XRCC1 BRCT I domain in mammalian DNA single-strand break repair. Mol Cell Biol 2002; 22: 2556-2563.
41. Feng L, Lin T, Uranishi H, Gu W, Xu Y. Functional analysis of the roles of posttranslational modifications at the p53C terminus in regulating p53 stability and activity. Mol Cell Biol 2005; 25: 5389-5395.
42. Feuerborn A, Moritz C, Von Bonin F, et al. Dysfunctional p53 deletion mutants in cell lines derived from Hodgkin's lymphoma. Leuk Lymphoma 2006; 47: 1932-1940.
43. Kim LH, Peh SC, Poppema S. Expression of retinoblastoma protein and P16 proteins in classic Hodgkin lymphoma: Relationship with expression of p53 and presence of Epstein-Barr virus in the regulation of cell growth and death. Hum Pathol 2006; 37: 92-100.
44. Pakakasama S, Sirirat T, Kanchanachumpol S, et al. Genetic polymorphisms and haplotypes of DNA repair genes in childhood acute lymphoblastic leukemia. Pediatr Blood Cancer 2007; 48: 16-20.
45. Vodicka P, Stetina R, Polakova V, et al. Association of DNA repair polymorphisms with DNA repair functional outcomes in healthy human subjects. Carcinogenesis 2007; 28: 657-664.
46. Huang M, Dinney CP, Lin X, et al. High-order interactions among genetic variants in DNA base excision repair pathway genes and smoking in bladder cancer susceptibility. Cancer Epidemiol Biomarkers Prev 2007; 16: 84-91.
47. Andrew AS, Karagas MR, Nelson HH, et al. DNA repair polymorphisms modify bladder cancer risk: A multi-factor analytic strategy. Hum Hered 2008; 65: 105-118.
48. De Ruyck K, Szaumkessel M, De Rudder I, et al. Polymorphisms in base-excision repair and nucleotide-excision repair genes in relation to lung cancer risk. Mutat Res 2007; 631: 101-110.
49. Liu Y, Scheurer ME, El-Zein R, et al. Association and interactions between DNA repair gene polymorphisms and adult glioma. Cancer Epidemiol Biomarkers Prev 2009; 18: 204-214.
50. Popanda O, Schattenberg T, Phong CT, et al. Specific combinations of DNA repair gene variants and increased risk for non-small cell lung cancer. Carcinogenesis 2004; 25: 2433-2441.
51. Berkovich E, Monnat RJ, Jr., Kastan MB. Roles of ATM and NBS1 in chromatin structure modulation and DNA double-strand break repair. Nat Cell Biol 2007; 9: 683-690.
52. Puebla-Osorio N, Zhu C. DNA damage and repair during lymphoid development: Antigen receptor diversity, genomic integrity and lymphomagenesis. Immunol Res 2008; 41: 103-122.
53. Bartkova J, Tommiska J, Oplustilova L, et al. Aberrations of the MRE11-RAD50-NBS1 DNA damage sensor complex in human breast cancer: MRE11 as a candidate familial cancer-predisposing gene. Mol Oncol 2008; 2: 296-316.
54. Cybulski C, Górski B, Debniak T, et al. NBS1 is a prostate cancer susceptibility gene. Cancer Res 2004; 64: 1215-1219.
55. Lu M, Lu J, Yang X, et al. Association between the NBS1 E185Q polymorphism and cancer risk: A meta-analysis. BMC Cancer 2009; 9: 124.
56. Gładkowska-Dura M, Dzierzanowska-Fangrat K, Dura WT, et al. Unique morphological spectrum of lymphomas in Nijmegen breakage syndrome (NBS) patients with high frequency of consecutive lymphoma formation. J Pathol 2008; 216: 337-344.
57. Vineis P, Manuguerra M, Kavvoura FK, et al. A field synopsis on low-penetrance variants in DNA repair genes and cancer susceptibility. J Natl Cancer Inst 2009; 101: 24-36.
58. Compton SA, Choi JH, Cesare AJ, et al. Xrcc3 and Nbs1 are required for the production of extrachromosomal telomeric circles in human alternative lengthening of telomere cells. Cancer Res 2007; 67: 1513-1519.
59. Sale JE, Calandrini DM, Takata M, et al. Ablation of XRCC2/3 transforms immunoglobulin V gene conversion into somatic hypermutation. Nature 2001; 412: 921-926.